PHI1.DE
Koninklijke Philips N.V. [PHI1.DE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PHI1.DE Stock Summary
Top 10 Correlated Stocks
PHI1.DE
In the News
PHI1.DE Financial details
PHI1.DE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 20.24 | 20.6 | 18.16 | 19.36 | 19.8 | |
| Net income per share | 1.21 | 1.25 | 0.65 | -1.76 | -0.51 | |
| Operating cash flow per share | 2.11 | 2.93 | 1.72 | -0.19 | 2.33 | |
| Free cash flow per share | 1.06 | 1.94 | 0.92 | -1.06 | 1.63 | |
| Cash per share | 1.48 | 3.4 | 2.44 | 1.28 | 2.04 | |
| Book value per share | 13.09 | 12.52 | 15.28 | 14.39 | 13.11 | |
| Tangible book value per share | 0.52 | 0.94 | 0.2 | -0.52 | -11.86 | |
| Share holders equity per share | 13.09 | 12.52 | 15.28 | 14.39 | 13.11 | |
| Interest debt per share | 5.9 | 7.53 | 7.59 | 9.18 | 8.79 | |
| Market cap | 39.62B | 40.41B | 29.7B | 12.41B | 19.42B | |
| Enterprise value | 43.65B | 44.12B | 34.38B | 19.44B | 25.24B | |
| P/E ratio | 33.92 | 34.05 | 48.53 | -7.67 | -41.68 | |
| Price to sales ratio | 2.03 | 2.07 | 1.73 | 0.7 | 1.07 | |
| POCF ratio | 19.51 | 14.55 | 18.23 | -71.76 | 9.1 | |
| PFCF ratio | 38.92 | 22.02 | 34.3 | -12.68 | 13.03 | |
| P/B Ratio | 3.15 | 3.4 | 2.06 | 0.94 | 1.61 | |
| PTB ratio | 3.15 | 3.4 | 2.06 | 0.94 | 1.61 | |
| EV to sales | 2.24 | 2.26 | 2 | 1.09 | 1.39 | |
| Enterprise value over EBITDA | 13.79 | 13.73 | 17.02 | 13.08 | 14.96 | |
| EV to operating cash flow | 21.49 | 15.89 | 21.1 | -112.39 | 11.82 | |
| EV to free cash flow | 42.87 | 24.05 | 39.7 | -19.86 | 16.93 | |
| Earnings yield | 0.03 | 0.03 | 0.02 | -0.13 | -0.02 | |
| Free cash flow yield | 0.03 | 0.05 | 0.03 | -0.08 | 0.08 | |
| Debt to equity | 0.43 | 0.58 | 0.48 | 0.62 | 0.64 | |
| Debt to assets | 0.2 | 0.25 | 0.23 | 0.27 | 0.26 | |
| Net debt to EBITDA | 1.27 | 1.15 | 2.31 | 4.73 | 3.45 | |
| Current ratio | 1.36 | 1.45 | 1.39 | 1.29 | 1.2 | |
| Interest coverage | 7.06 | 7.56 | 2.94 | -0.45 | 1.13 | |
| Income quality | 1.7 | 2.3 | 2.66 | 0.11 | -4.68 | |
| Dividend Yield | 0.01 | 0 | 0.02 | 0.03 | 0 | |
| Payout ratio | 0.39 | 0 | 0.79 | -0.25 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | |
| Research and developement to revenue | 0.1 | 0.1 | 0.11 | 0.12 | 0.1 | |
| Intangibles to total assets | 0.45 | 0.4 | 0.46 | 0.45 | 0.78 | |
| Capex to operating cash flow | -0.5 | -0.34 | -0.47 | 4.66 | -0.3 | |
| Capex to revenue | -0.05 | -0.05 | -0.04 | -0.05 | -0.04 | |
| Capex to depreciation | -0.72 | -0.62 | -0.58 | -0.5 | -0.51 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Graham number | 18.9 | 18.78 | 14.93 | 23.85 | 12.24 | |
| ROIC | 0.07 | 0.06 | 0.03 | 0 | 0.02 | |
| Return on tangible assets | 0.08 | 0.07 | 0.04 | -0.1 | -0.07 | |
| Graham Net | -8.32 | -8.29 | -10.04 | -11.88 | -11.73 | |
| Working capital | 2.49B | 3.49B | 2.9B | 2.33B | 1.65B | |
| Tangible asset value | 505M | 890M | 187M | -481M | -10.88B | |
| Net current asset value | -4.92B | -4.59B | -6.14B | -7.15B | -7.4B | |
| Invested capital | 0.43 | 0.58 | 0.48 | 0.62 | 0.64 | |
| Average receivables | 4.45B | 4.51B | 4.14B | 4.15B | 4.15B | |
| Average payables | 2.2B | 2.1B | 2B | 1.92B | 1.94B | |
| Average inventory | 2.72B | 2.88B | 3.22B | 3.75B | 3.77B | |
| Days sales outstanding | 88.28 | 80.46 | 84.4 | 88.8 | 79.41 | |
| Days payables outstanding | 71.89 | 71.92 | 68.41 | 67.56 | 65.26 | |
| Days of inventory on hand | 95.42 | 101.58 | 126.08 | 138.99 | 118.85 | |
| Receivables turnover | 4.13 | 4.54 | 4.32 | 4.11 | 4.6 | |
| Payables turnover | 5.08 | 5.08 | 5.34 | 5.4 | 5.59 | |
| Inventory turnover | 3.83 | 3.59 | 2.9 | 2.63 | 3.07 | |
| ROE | 0.09 | 0.1 | 0.04 | -0.12 | -0.04 | |
| Capex per share | -1.05 | -0.99 | -0.81 | -0.88 | -0.7 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 6.14 | 4.73 | 4.86 | 4.87 | 0 | |
| Net income per share | -0.13 | -0.75 | 0.08 | 0.1 | 0 | |
| Operating cash flow per share | 0.12 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0.12 | 0 | 0 | 0 | 0 | |
| Cash per share | 1.34 | 1.34 | 1.05 | 1.05 | 0 | |
| Book value per share | 15.01 | 15.07 | 13.18 | 13.25 | 0 | |
| Tangible book value per share | -0.54 | 0 | -1.31 | 0 | 0 | |
| Share holders equity per share | 15.01 | 15.07 | 13.18 | 13.25 | 0 | |
| Interest debt per share | 9.39 | 0.11 | 9.02 | 0.1 | 0 | |
| Market cap | 11.9B | 14.26B | 18.3B | 17.39B | 0 | |
| Enterprise value | 18.93B | 15.45B | 25.56B | 18.36B | 5.74B | |
| P/E ratio | -26.33 | -5.38 | 63.55 | 49.4 | 0 | |
| Price to sales ratio | 2.19 | 3.42 | 4.09 | 3.89 | 0 | |
| POCF ratio | 114.43 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 114.43 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0.9 | 1.07 | 1.51 | 1.43 | 0 | |
| PTB ratio | 0.9 | 1.07 | 1.51 | 1.43 | 0 | |
| EV to sales | 3.49 | 3.71 | 5.72 | 4.11 | 1.13 | |
| Enterprise value over EBITDA | 150.24 | -26.4 | 127.79 | 83.06 | -102.57 | |
| EV to operating cash flow | 182.02 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 182.02 | 0 | 0 | 0 | 0 | |
| Earnings yield | -0.01 | -0.05 | 0 | 0.01 | 0 | |
| Free cash flow yield | 0.01 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.62 | 0 | 0.68 | 0 | 0.63 | |
| Debt to assets | 0.27 | 0 | 0.28 | 0 | 0.26 | |
| Net debt to EBITDA | 55.79 | -2.02 | 36.28 | 4.38 | -102.57 | |
| Current ratio | 1.29 | 0 | 1.2 | 0 | 1.2 | |
| Interest coverage | 1.86 | -6.27 | 2.63 | 2.46 | 0.63 | |
| Income quality | -0.99 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | |
| Research and developement to revenue | 0.09 | 0.13 | 0.1 | 0.1 | 0.09 | |
| Intangibles to total assets | 0.45 | 0 | 0.45 | 0 | 0.44 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.02 | 0 | 0 | 0 | 0 | |
| Graham number | 6.57 | 15.97 | 4.82 | 5.34 | 0 | |
| ROIC | -0.12 | -0.04 | 0.01 | 0.01 | 0 | |
| Return on tangible assets | -0.01 | 0 | 0 | 0 | 0 | |
| Graham Net | -12.4 | 1.34 | -12.42 | 1.05 | 0 | |
| Working capital | 2.33B | 1.18B | 1.62B | 968M | 1.66B | |
| Tangible asset value | -481M | 0 | -1.2B | 0 | -1.01B | |
| Net current asset value | -7.15B | 1.18B | -7.66B | 968M | -7.41B | |
| Invested capital | 0.62 | 0 | 0.68 | 0 | 0.63 | |
| Average receivables | 2.17B | 2.17B | 1.93B | 1.93B | 2.13B | |
| Average payables | 984M | 984M | 823M | 823M | 958.5M | |
| Average inventory | 2.02B | 2.02B | 2.05B | 2.05B | 1.75B | |
| Days sales outstanding | 71.99 | 0 | 77.84 | 0 | 75.67 | |
| Days payables outstanding | 55.33 | 0 | 59.07 | 0 | 52.87 | |
| Days of inventory on hand | 113.84 | 0 | 146.95 | 0 | 96.29 | |
| Receivables turnover | 1.25 | 0 | 1.16 | 0 | 1.19 | |
| Payables turnover | 1.63 | 0 | 1.52 | 0 | 1.7 | |
| Inventory turnover | 0.79 | 0 | 0.61 | 0 | 0.93 | |
| ROE | -0.01 | -0.05 | 0.01 | 0.01 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
PHI1.DE Frequently Asked Questions
What is Koninklijke Philips N.V. stock symbol ?
Koninklijke Philips N.V. is a NL stock and trading under the symbol PHI1.DE
What is Koninklijke Philips N.V. stock quote today ?
Koninklijke Philips N.V. stock price is $18.81 today.
Is Koninklijke Philips N.V. stock public?
Yes, Koninklijke Philips N.V. is a publicly traded company.
Company Profile
- Volume Average 10.11K
- Market Capitalization 17.31B
- Employee 69.66K
- CEO Mr. Roy Jakobs
- Headquarters Amsterdam,NL
- IPO Date 2007-12-28
-
Website
https://www.philips.com 
Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
